10-Q: Elevance Health Reports Mixed Q3 Results Amidst Medicaid Membership Shifts

Elevance Health's Q3 2024 results show a mix of revenue growth and profit challenges, influenced by Medicaid membership changes and strategic business adjustments.

Summary

• Elevance Health reported a 5.3% increase in operating revenue to $44.7 billion for Q3 2024, driven by premium rate increases and growth in CarelonRx.
• Net income for Q3 2024 decreased by 22.5% to $1.0 billion compared to Q3 2023, primarily due to a decrease in operating gain and a reduction in the gain from the sale of the life and disability businesses.
• For the nine months ended September 30, 2024, net income increased by 7.7% to $5.6 billion, supported by higher investment income and the gain on the sale of the life and disability businesses.
• Medical membership declined by 3.3% year-over-year, mainly due to Medicaid attrition and some market exits, partially offset by growth in other segments.
• The company's 2025 Medicare Star Ratings indicate that 38% of Medicare Advantage members are in plans rated 4.0 stars or higher, which is expected to reduce 2026 operating revenue by approximately $183 million.
• Elevance Health made a $2.58 billion investment in Mosaic Health, a joint venture, and acquired Paragon Healthcare, Inc. to expand its care delivery and pharmacy services.
• The company also completed the sale of its life and disability businesses to StanCorp Financial Group, Inc. for a gain of $201 million.
• Elevance Health is facing ongoing litigation, including the Blue Cross Blue Shield Antitrust Litigation, for which they have accrued $666 million for a settlement.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with positive revenue growth but significant challenges in profitability and membership. The legal accrual and Medicare Star Rating impact add to the negative sentiment, resulting in a neutral to slightly negative outlook.

Positives

• Operating revenue increased by 5.3% in Q3 2024 and 1.9% for the nine months ended September 30, 2024.
• Net investment income increased due to higher income from fixed maturity securities.
• The company completed the sale of its life and disability businesses, resulting in a gain of $201 million.
• Elevance Health made strategic investments in Mosaic Health and acquired Paragon Healthcare, Inc. to expand its services.
• The company is actively managing costs, resulting in a decrease in the operating expense ratio.
• The company's 2024 Star Ratings improved from 34% to 53% of Medicare Advantage members in plans rated at least 4.0 Stars or higher.

Negatives

• Net income decreased by 22.5% in Q3 2024 compared to Q3 2023.
• Medical membership declined by 3.3% year-over-year, primarily due to Medicaid attrition.
• The company accrued $666 million for the Provider Settlement Agreement related to the Blue Cross Blue Shield Antitrust Litigation.
• The 2025 Medicare Star Ratings are expected to reduce 2026 operating revenue by approximately $183 million.
• Medicaid rates are inadequate to cover medical cost trends, impacting the Health Benefits segment's operating gain.

Risks

• Medicaid membership attrition due to eligibility redeterminations is negatively impacting overall membership.
• The company faces ongoing litigation, including the Blue Cross Blue Shield Antitrust Litigation, which could result in significant liabilities.
• The 2025 Medicare Star Ratings are expected to reduce 2026 operating revenue.
• Medical cost trends, particularly in the Medicaid segment, are impacting profitability.
• Changes in regulations and government funding could impact revenue and operations.
• The company is exposed to risks related to cyber-attacks and data security incidents.

Future Outlook

Elevance Health expects growth in its commercial plans, including through the Public Exchanges, as members who have lost Medicaid coverage seek coverage elsewhere. The company also anticipates a reduction to its 2026 operating revenue of approximately $183 million due to the 2025 Medicare Star Ratings, but plans to mitigate the financial impact through various strategies.

Management Comments

• Management implemented the 2023-2024 Business Efficiency Program to enhance operating efficiency, refine the focus of investments and optimize the physical footprint.
• Management believes that cash on hand, future operating cash receipts, investments and funds available under the commercial paper program, the 5-Year Facility and borrowings available from the FHLBs will be adequate to fund expected cash disbursements over the next twelve months.

Industry Context

The healthcare industry is experiencing significant shifts due to regulatory changes, including Medicaid eligibility redeterminations and the Inflation Reduction Act. Elevance Health is adapting to these changes by expanding its presence in the Public Exchanges and diversifying its service offerings through acquisitions and strategic partnerships. The company is also facing increased competition and cost pressures, requiring ongoing efforts to manage medical costs and improve operational efficiency.

Comparison to Industry Standards

• Elevance Health's medical membership decline of 3.3% is notable compared to industry trends, where some insurers are seeing growth in certain segments, particularly Medicare Advantage.
• The company's operating revenue growth of 5.3% in Q3 2024 is in line with some of its peers, but the decrease in net income of 22.5% is a concern, indicating potential challenges in cost management.
• The $666 million accrual for the Provider Settlement Agreement is a significant expense, highlighting the ongoing legal risks faced by large healthcare insurers.
• The expected $183 million reduction in 2026 operating revenue due to Medicare Star Ratings is a common challenge in the industry, where performance metrics directly impact revenue.
• Elevance Health's strategic investments in Mosaic Health and Paragon Healthcare, Inc. are similar to moves by other large insurers to expand their care delivery and pharmacy services, aiming to improve patient outcomes and reduce costs.

Legal Proceedings

• Elevance Health is a defendant in multiple lawsuits related to the Blue Cross Blue Shield Antitrust Litigation.
• The company is involved in a lawsuit with the U.S. Department of Justice regarding Medicare risk adjustment.
• Elevance Health is also involved in other pending and threatened litigation of the character incidental to its business.

Stakeholder Impact

• Shareholders may be concerned about the decrease in net income and the potential impact of the Medicare Star Ratings.
• Employees may be affected by the ongoing business efficiency program and potential changes in job functions.
• Customers may experience changes in coverage and service offerings due to the company's strategic adjustments.
• Providers may be impacted by changes in contracting and reimbursement rates.
• Creditors may be concerned about the company's debt levels and ongoing litigation.

Next Steps

• The company will continue to monitor and manage the impact of Medicaid eligibility redeterminations.
• Elevance Health will focus on mitigating the financial impact of the 2025 Medicare Star Ratings.
• The company will continue to defend itself in ongoing litigation, including the Blue Cross Blue Shield Antitrust Litigation.
• Elevance Health will work to integrate recent acquisitions and expand its service offerings.
• The company will continue to evaluate and manage its capital allocation strategy.

Key Dates

Keywords

Elevance Health, Medicaid, Medicare, Healthcare, Insurance, Pharmacy, CarelonRx, Membership, Financial Results, Litigation, Acquisition, Divestiture